{"entity":{"id":"nct06033586","kind":"trial","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","aka":["THRIVE"],"tldr":"A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.","summary":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera is a phase 3 interventional study registered as NCT06033586 by Protagonist Therapeutics, Inc., with 46 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Open-label rusfertide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06033586","url":"https://clinicaltrials.gov/study/NCT06033586"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["rusfertide"],"companies":["protagonist-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06033586","phase":"3","setting":"An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)","sponsor":"Protagonist Therapeutics, Inc.","started":"2024-01-22","startedType":"actual","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06033586/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"drug":[{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/"}],"company":[{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/"}]}}